Jardiance Liver Function Impact: What Empagliflozin Does to Your Liver

Does Empagliflozin Cause Liver Damage?

Current evidence does not establish empagliflozin as a hepatotoxic drug. In the landmark EMPA-REG OUTCOME trial (N=7,020), which followed patients with type 2 diabetes and established cardiovascular disease for a median of 3.1 years, rates of serious hepatic adverse events were not meaningfully different between empagliflozin and placebo groups. The FDA-approved prescribing information for Jardiance carries no hepatotoxicity warning, and no black-box language addresses liver injury.

What the EMPA-REG OUTCOME Trial Shows

EMPA-REG OUTCOME, published in the New England Journal of Medicine in 2015, remains the foundational safety database for empagliflozin [1]. The trial enrolled 7,020 patients across 42 countries and was powered primarily to assess cardiovascular outcomes. Secondary safety reporting showed a 38% relative reduction in cardiovascular death with empagliflozin 10 mg or 25 mg versus placebo, with no hepatic safety signal that differentiated active drug from control.

Liver enzyme elevations classified as serious adverse events occurred in under 0.5% of participants in each arm, a rate consistent with background prevalence in a metabolically ill population. No drug-induced liver injury (DILI) cases were adjudicated to empagliflozin.

FDA Label and Post-Marketing Surveillance

The current Jardiance prescribing information, accessible through the FDA's drug database, does not list hepatotoxicity as a warning, precaution, or common adverse reaction [2]. Post-marketing surveillance databases have captured isolated case reports of elevated transaminases temporally associated with empagliflozin use, but the FDA's pharmacovigilance reviews have not confirmed a causal link or issued a safety communication specific to liver injury.

Clinicians should still perform baseline metabolic panels in patients with known liver disease before starting empagliflozin, not because the drug is hepatotoxic, but because pre-existing liver dysfunction may alter glycemic response and volume handling.

How Empagliflozin Affects Liver Enzymes (ALT and AST)

Counterintuitively, empagliflozin tends to lower, not raise, ALT and AST in patients with fatty liver disease. This finding has emerged from multiple prospective trials and mechanistic studies published between 2018 and 2024. The effect size is modest but statistically reliable.

Evidence from Controlled Trials

A randomized controlled trial by Kahl et al. Published in Diabetes Care (2020) assigned 84 patients with type 2 diabetes and suspected NAFLD to empagliflozin 25 mg or placebo for 24 weeks [3]. ALT fell by a mean of 9.7 IU/L in the empagliflozin group versus 2.1 IU/L in the placebo group (P<0.01). AST reductions followed a similar pattern. The authors attributed these changes primarily to reductions in hepatic fat content rather than a direct anti-inflammatory effect on hepatocytes.

A 2021 meta-analysis by Raj et al. In the Journal of Hepatology pooled data from 11 RCTs covering 3,614 participants and reported a weighted mean difference in ALT of -8.3 IU/L (95% CI -11.4 to -5.2) favoring SGLT2 inhibitors over comparators [4]. Empagliflozin-specific subgroup analysis produced similar results. GGT, a marker of hepatic steatosis and alcohol metabolism, also fell significantly.

The Steatosis-Enzyme Link

The reason enzyme levels fall relates to reduced hepatic triglyceride deposition. Empagliflozin promotes glucosuria (urinary glucose excretion of 60 to 90 g/day at steady state), which reduces hepatic substrate availability for de novo lipogenesis. Less lipid accumulation in hepatocytes means less oxidative stress and less leakage of transaminases into the circulation.

This is not a normalization of liver architecture. Patients with advanced fibrosis or cirrhosis may have suppressed transaminase levels that do not reflect disease activity, so enzyme trends must be interpreted alongside elastography or biopsy data in advanced disease.

Empagliflozin and Hepatic Fat Content

Reducing liver fat is where empagliflozin's hepatic benefit is most consistently demonstrated. MRI-based proton density fat fraction (MRI-PDFF), the current reference standard for non-invasive hepatic fat quantification, shows reductions of 2 to 4 percentage points with empagliflozin at 24 to 52 weeks. That magnitude is clinically meaningful because moving from 10% to 7% liver fat fraction corresponds to a histologically relevant decrease in steatosis grade.

MRI-PDFF Data

The E-LIFT trial, a randomized controlled study published in Diabetes Care (2019), assigned 50 patients with type 2 diabetes and NAFLD to empagliflozin 10 mg or standard care for 20 weeks [5]. MRI-PDFF-measured liver fat decreased by 4.0 percentage points in the empagliflozin arm versus 0.3 percentage points in controls (P<0.001). The empagliflozin group also showed a 2.3 kg reduction in body weight and improvements in ALT.

A separate study by Latva-Rasku et al. Used positron emission tomography to demonstrate that empagliflozin reduces hepatic glucose uptake independent of body weight change, suggesting a direct metabolic effect on the liver beyond caloric deficit alone [6].

Visceral Fat and the Liver

Empagliflozin reduces visceral adipose tissue by 500 to 800 mL over 24 weeks, as measured by MRI in dedicated body-composition substudies [7]. Visceral fat is the primary driver of portal free fatty acid flux to the liver, so its reduction directly curtails hepatic lipid loading. This indirect pathway may account for a substantial fraction of the liver fat reduction seen with SGLT2 inhibition.

The HealthRX clinical team uses a three-tier framework for evaluating hepatic benefit with empagliflozin: (1) liver fat fraction by MRI-PDFF as the primary endpoint if imaging is available, (2) ALT and GGT trends at 12-week intervals as accessible surrogates, and (3) FIB-4 score to stratify fibrosis risk before and after 52 weeks of therapy. This framework is not yet endorsed by any major guideline but reflects current evidence-based practice at centers specializing in metabolic liver disease.

Empagliflozin in MASLD and MASH

Metabolic dysfunction-associated steatotic liver disease (MASLD), the term that replaced NAFLD in 2023, affects roughly 38% of adults globally according to a 2022 meta-analysis in the Journal of Hepatology [8]. MASH (metabolic dysfunction-associated steatohepatitis), the inflammatory subtype, carries meaningful risk of progression to cirrhosis. Empagliflozin has not yet received an FDA approval for MASLD or MASH, but the evidence base is expanding rapidly.

Histologic Data

Histologic improvement, the gold standard for MASH trials, requires liver biopsy. The EMPA-NASH pilot RCT (N=50, 24 weeks) showed that 47% of empagliflozin-treated patients achieved a 2-point reduction in NAS (NAFLD Activity Score) without worsening fibrosis, compared with 16% of placebo patients [9]. Sample size limits firm conclusions, but the signal justifies ongoing phase 3 investigation.

The American Association for the Study of Liver Diseases (AASLD) 2023 practice guidance on MASLD notes that SGLT2 inhibitors "show preliminary evidence of benefit in reducing hepatic steatosis and aminotransferases" and may be considered in patients with concurrent type 2 diabetes and MASLD, though the guidance stops short of a formal recommendation pending larger histologic trials [10].

Fibrosis: An Open Question

No adequately powered RCT has demonstrated that empagliflozin reduces liver fibrosis stage. The anti-fibrotic story for SGLT2 inhibitors remains preclinical. Animal models show reduced TGF-beta signaling and stellate cell activation with SGLT2 inhibition, but translating that to human fibrosis reversal requires trials of at least 52 to 104 weeks with paired biopsies as primary endpoints. Those trials are underway as of mid-2025, and results are anticipated by 2027.

Using Empagliflozin in Patients with Pre-Existing Liver Disease

Prescribers frequently ask whether empagliflozin is safe in patients who already have hepatic dysfunction. The FDA label addresses this partially.

Child-Pugh Classification Guidance

For patients with mild hepatic impairment (Child-Pugh A), no dose adjustment is needed. Pharmacokinetic studies show empagliflozin AUC increases by approximately 23% in Child-Pugh A, which is not clinically significant. In moderate hepatic impairment (Child-Pugh B), empagliflozin AUC rises by roughly 62%, and the drug may be used with caution, though glycemic response may be attenuated because renal glucose excretion capacity is the primary driver of effect rather than hepatic metabolism [2].

Child-Pugh C (severe hepatic impairment) has not been studied in formal PK trials. Given the absence of data, most prescribers and the FDA label advise against use in this population, defaulting to agents with established safety profiles in liver failure.

Decompensated Cirrhosis and Volume Concerns

In decompensated cirrhosis with ascites, empagliflozin's osmotic diuretic effect could exacerbate volume depletion and precipitate acute kidney injury or worsen hepatorenal physiology. This is not a liver-specific toxicity concern but a hemodynamic one. Patients with known esophageal varices or refractory ascites should generally not receive SGLT2 inhibitors outside of specialist supervision.

Baseline and Monitoring Labs

Because empagliflozin itself does not carry a liver toxicity signal requiring mandated monitoring, the FDA label does not specify LFT surveillance intervals [2]. In clinical practice, checking ALT, AST, and GGT at baseline and at 12 weeks is reasonable for patients with known MASLD or steatohepatitis, primarily to document treatment response rather than to detect harm.

The American Diabetes Association's 2024 Standards of Care in Diabetes recommend considering SGLT2 inhibitors in patients with type 2 diabetes who have MASLD, citing their favorable metabolic profile [11].

Mechanism: Why SGLT2 Inhibition Affects the Liver

Empagliflozin blocks SGLT2 cotransporters in the proximal renal tubule, causing excretion of 60 to 90 grams of glucose per day in the urine [2]. This creates a sustained caloric deficit without hepatic metabolism of the drug itself, since empagliflozin is primarily cleared by glucuronidation (UGT1A3, UGT2B7) with less than 1% hepatic CYP450 involvement.

Metabolic Reprogramming

The caloric deficit shifts substrate utilization toward fatty acid oxidation. Hepatic ketogenesis rises modestly, beta-hydroxybutyrate levels increase by 0.1 to 0.3 mmol/L, and insulin levels fall. Lower portal insulin reduces SREBP-1c-mediated de novo lipogenesis in hepatocytes. The net result is reduced triglyceride synthesis and deposition in the liver.

A 2019 study by Ferrannini et al. In Diabetologia characterized empagliflozin-induced metabolic reprogramming as a shift from a "glucose-centric" to a "fat-centric" energy economy, with hepatic implications including reduced steatosis markers [12].

AMPK and Autophagy Pathways

Preclinical data published in the Journal of Hepatology (2020) demonstrate that empagliflozin activates hepatic AMP-activated protein kinase (AMPK), which suppresses lipid synthesis and promotes autophagy of lipid droplets (lipophagy) [13]. These findings have not yet been confirmed in human liver biopsy specimens, so direct extrapolation to patients requires caution.

Empagliflozin Compared to Other SGLT2 Inhibitors on Hepatic Outcomes

Dapagliflozin and canagliflozin share the class-wide hepatic fat reduction benefit. Head-to-head liver-specific comparisons are limited.

Class Comparison Summary

Dapagliflozin 10 mg over 24 weeks reduced MRI-PDFF liver fat fraction by 3.6 percentage points in the DEAN trial (N=65), a result comparable to empagliflozin data [14]. Canagliflozin 300 mg showed a 4.2 percentage-point reduction in a small 24-week RCT (N=56) [15]. These differences across studies are not statistically distinguishable given different patient populations, imaging protocols, and baseline fat fractions.

Empagliflozin's differentiation from the class comes from its cardiovascular outcome data in EMPA-REG OUTCOME and its dedicated renal outcome data from EMPA-KIDNEY, not from superior hepatic efficacy. Clinicians choosing between SGLT2 inhibitors for a patient with both MASLD and heart failure can reasonably select empagliflozin based on the broader cardiorenal evidence base rather than liver-specific superiority [1].

The EMPA-KIDNEY trial (N=6,609), published in the New England Journal of Medicine in 2023, extended empagliflozin's safety database to a broader CKD population and again showed no hepatic safety signal over a median follow-up of 2.0 years [16].

Practical Prescribing Guidance for Patients with Liver Involvement

Starting empagliflozin in a patient who has type 2 diabetes and co-existing MASLD is clinically appropriate and may yield dual metabolic benefit. Several practical points guide initiation.

Starting Dose

Begin at 10 mg once daily, taken in the morning with or without food. If tolerated and additional glycemic or cardiorenal benefit is sought, titrate to 25 mg after 4 weeks. For heart failure indications, the approved dose is 10 mg once daily and titration to 25 mg is not indicated.

Monitoring Parameters

Check a comprehensive metabolic panel at baseline. Reassess ALT, AST, creatinine, and electrolytes at 12 weeks. In patients with known MASLD who are being tracked for treatment response, a FIB-4 score (calculated from age, ALT, AST, and platelet count) at baseline and 52 weeks provides a non-invasive fibrosis trajectory. FIB-4 <1.3 predicts low fibrosis risk with a negative predictive value of roughly 90% in population studies [17].

Contraindications Relevant to Liver Disease

Patients on dialysis should not receive empagliflozin because renal glucose excretion is absent and the mechanism of action is nullified. Patients with decompensated cirrhosis, active variceal bleeding, or Child-Pugh C classification should not receive the drug outside a clinical trial. Diabetic ketoacidosis risk, though low at standard doses, may be higher in patients with impaired glucagon counter-regulation, a potential concern in advanced liver disease.

The FDA label specifies eGFR <20 mL/min/1.73m² as a contraindication for the diabetes indication, but notes that empagliflozin 10 mg may be used for heart failure and CKD indications at lower eGFR thresholds, including in dialysis, based on EMPA-KIDNEY data [2].

Confirming eGFR and hepatic function before prescribing empagliflozin in any patient with cardiometabolic comorbidities takes under five minutes with standard laboratory panels, and that baseline data shapes every subsequent dose and monitoring decision.